Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma.

Stephanie VairyGwénaël Le TeuffFrancisco BautistaEmilie De CarliAnne-Isabelle BertozziAnne PagnierFanny FouyssacKarsten NysomIsabelle AertsPierre LeblondFrederic MillotClaire BergerSandra CanaleAngelo PaciVianney PoinsignonAurelie ChevanceMonia EzzalfaniDominique VidaudAngela Di GiannataleRaquel Hladun-AlvaroFrancois M PetitGilles VassalBirgit GeoergerMarie-Cécile Le DeleyJacques Grill

Published in: Neuro-oncology advances (2020)

Vinblastine and nilotinib combination was mostly limited by myelosuppression and dermatologic toxicity. The efficacy of the combination at the RP2D is currently evaluated in a randomized phase II trial comparing this regimen to vinblastine alone.

Keyphrases

low grade
young adults
high grade
physical activity
oxidative stress
clinical trial
open label
middle aged